Heron Therapeutics Inc. hit a home run in dual phase III trials examining its non-opioid candidate, HTX-011, to control postoperative pain in patients following bunionectomy and hernia repair.
In a recent revelation, Chinese police disclosed that four former employees of HTX (formerly Huobi) were involved in implanting Trojans in cryptocurrency wallets, resulting in the theft of over 40,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback